Hims & Hers (HIMS) has taken a beating, with the stock down roughly 70% from its $70 peak and now trading below $21 per share. But the story's changing. After the company's Novo Nordisk (NVO) deal and ...

Hims & Hers is a Strong Buy, as shares appear historically cheap due to temporary margin compression and regulatory concerns. HIMS's recurring revenue model, 70%+ gross margins, and rapid subscriber ...

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, operates as a digital healthcare platform built on proprietary technology that integrates care delivery, data and fulfillment ...

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, operates as a connected healthcare platform rather than a single-product provider, consistently linking consumers with ...

Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international expansion opportunities. Geographical and product expansion, vertical ...

・Analysts at BofA nearly doubled their price target for HIMS stock following the company’s deal with Novo. ・The firm now has a price target of $23, up from $12.5, while the rating has been upgraded to ...